AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
2001 JUL 4 - (NewsRx.com & NewsRx.net) --
Scientists in collaboration with Aphton Corporation (Nasdaq:APHT) recently published a peer-reviewed article with the new findings that the genes for both the gastrointestinal hormone gastrin and its receptor are "switched on" at the earliest stages of premalignancy in stomach cells, helping to fuel their progression to cancer.
Thus, gastrin is established as an important growth factor in pushing the progression of the pre-malignant stomach cells from the earliest stage, metaplasia, through dysplasia and on to adenocarcinomas. Similarly, the scientists established the very early role of gastrin in fueling progression of cancer in colon cells.
The researchers examined numerous patient biopsies encompassing a range of tissue types. All tissue samples were extensively assayed for the presence of gastrin and its precursor forms, such as gly-gastrin, and for the presence of gastrin receptors. These assays showed that both gastrin and the gastrin receptors were activated in all of the stages. Additionally, the researchers found that expression of both gastrin and its receptor were increased in the progression to cancer.
These results were published in an article titled, "Expression of gastrin in developing gastric adenocarcinoma," which appeared in the June 2001 issue of British Journal of Surgery.
In clinical trials, Aphton's anti-gastrin vaccine induced antibodies in patients that neutralize both gastrin 17 and gly-gastrin ...